Susan Graf
Vermögen: - $ am 31.08.2026
Vermögen: - $ am 31.08.2026
Susan E.
Graf is currently Director at Kaleo, Inc. since 2021, Independent Director at CG Oncology, Inc. since 2023, and Independent Director at Aardvark Therapeutics, Inc. since 2024.
Former roles include Chief Executive Officer at Akamara Therapeutics, Inc. from 2019 to 2021, Independent Chairman at Finch Therapeutics Group, Inc. from 2022 to 2024, Director at Vitrisa Therapeutics, Inc., Vice President-Corporate Development & Strategy at NPS Pharmaceuticals, Inc. from 2013 to 2015, and Chief Financial & Business Officer at Epizyme, Inc. from 2016 to 2018.
Education includes undergraduate studies at Purdue University and an MBA from The Leonard N Stern School of Business.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 04.06.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| 14.08.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CG ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 20.11.2023 |
| AARDVARK THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.11.2024 |
Kaleo, Inc.
Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Develops drug or device combination products | Direktor/Vorstandsmitglied | 01.12.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Vorsitzender | 01.03.2024 |
Akamara Therapeutics, Inc.
Akamara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Vorstandsvorsitzender | 01.05.2021 |
| EPIZYME, INC. | Finanzdirektor/CFO | 30.09.2018 |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2015 |
Vitrisa Therapeutics, Inc.
Vitrisa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products for the treatments of rare diseases | Health Technology |
Kaleo, Inc.
Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Develops drug or device combination products | Health Technology |
Purdue University
Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
The Leonard N Stern School of Business
The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. Medical/Nursing ServicesHealth Services Provides microbial therapy services | Health Services |
Vitrisa Therapeutics, Inc.
Vitrisa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics for obesity and metabolic diseases | Health Technology |
Akamara Therapeutics, Inc.
Akamara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen